EPIXD Epix Pharmaceuticals (MM)

EPIX Pharmaceuticals (NASDAQ: EPIXD) announced that chief executive officer Michael G. Kauffman, M.D., Ph.D. and other members of management are scheduled to commemorate the company's recent merger with Predix Pharmaceuticals by ringing the NASDAQ Stock Market closing bell on Tuesday, August 22, 2006 at 4:00 p.m. ET in New York City. "This is an excellent forum to celebrate the recent combination of EPIX and Predix," said Dr. Kauffman. "We are excited about our prospects for near-term and future growth with our novel angiographic agent Vasovist(TM) and our five internally discovered clinical-stage product candidates." "We would like to take this opportunity to thank all of our employees, partners and shareholders for their ongoing support as we enter the next phase of our mission to improve patients' lives by developing products to meet significant, unmet clinical needs," stated Andrew Uprichard, M.D., president of EPIX. Investor Conference Call Reminder EPIX has scheduled an investor conference call for August 23, 2006 at 8:00 a.m. Eastern Time to provide an overview of the combined company and discuss its progress in key programs. The live webcast can be accessed by visiting the investor relations section of the Company's website at http://www.epixpharma.com. The call can be accessed by dialing 1-800-659-1966 (domestic) or 617-614-2711 (international) five minutes prior to the start time and providing the pass code 48005474. A replay of the call will be available on the EPIX website approximately two hours after completion of the call and will be archived for two weeks. About EPIX Pharmaceuticals EPIX Pharmaceuticals is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has a blood-pool imaging agent approved and marketed in Europe (Vasovist(TM)), and five internally-discovered drug candidates currently in clinical trials targeting conditions such as anxiety, depression, Alzheimer's disease, cardiovascular disease and obesity. EPIX also has collaborations with leading organizations, including Amgen, Cystic Fibrosis Foundation Therapeutics, and Schering AG, Germany. For more information about EPIX, please visit the company's website at www.epixpharma.com. Note to Editors/Investors: As a result of the merger and reverse stock split, a "D" has been added to EPIX's NASDAQ trading symbol for 20 days following the closing of the merger on August 16, 2006.